Syntax Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Syntax Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$236K	Sell	678 -12	-2%	-$4.2K	0.21%	124
2023 Q2	$243K	Sell	690 -145	-17%	-$48.9K	0.2%	135
2023 Q1	$263K	Buy	835 +63	+8%	+$18.9K	0.2%	123
2022 Q4	$223K	Sell	772 -103	-12%	-$31.4K	0.19%	163
2022 Q3	$253K	Sell	875 -70	-7%	-$20.1K	0.22%	103
2022 Q2	$266K	Sell	945 -27	-3%	-$7.23K	0.22%	96
2022 Q1	$254K	Sell	972 -280	-22%	-$66.5K	0.21%	129
2021 Q4	$275K	Buy	+1,252	New	+$243K	0.2%	141

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Syntax Advisors's VRTX Position: Q3 2023 in Review

Syntax Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 1.7% in Q3 2023, selling an estimated $4.2K and leaving 678 shares worth $236K. The position accounts for 0.21% of the portfolio, ranked #124.

Syntax Advisors first reported a position in VRTX in Q4 2021 and has held it in 8 quarters since. The position peaked at $275K in Q4 2021. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

Syntax Advisors held 678 shares of Vertex Pharmaceuticals worth $236K as of Q3 2023.
Syntax Advisors sold 12 Vertex Pharmaceuticals shares in Q3 2023, an estimated $4.2K.
Vertex Pharmaceuticals made up 0.21% of Syntax Advisors's portfolio in Q3 2023, its #124 holding.
Syntax Advisors first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 8 quarters since.
Syntax Advisors's Vertex Pharmaceuticals position peaked at $275K in Q4 2021.
1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Syntax Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.